Lenvatinib plus PD-1 antibody for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old and agree to sign informed consent before any study tests.
- You must have non-small cell lung cancer (NSCLC) that is locally advanced (stage IIIB–IIIC) or metastatic (stage IV), not small cell lung cancer.
- Your tumor situation must match one of the study groups: (A) no EGFR/ALK/ROS1 gene changes and cancer returned after prior PD-1/PD-L1 therapy, (B) EGFR-sensitive mutation and/or ALK fusion with progression after the right targeted pills, or (C) not eligible for curative surgery/radiation and PD-L1 is low (TPS <1%).
- You must be able to show at least one measurable tumor spot on a scan, and brain metastases are allowed only if they’re stable after local treatment and you have measurable disease outside the brain.
- Your general health must be strong enough for study drug treatment (good activity level ECOG 0–1, enough blood counts and organ function, and survival expected over 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced lung cancer that stopped responding to a PD-1 inhibitor. The goal is to see if this new triple therapy can help shrink tumors or slow down the cancer.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.